This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by RÖSLER, A. Search for Related Content PubMed PubMed Citation Articles by RÖSLER, A.

The Natural History of Salt-Wasting Disorders of Adrenal and Renal Origin^*

Department of Endocrinology and Metabolism, Hebrew University-Hadassah Medical Center IL-91120 Jerusalem, Israel

Address requests for reprints to: Ariel Rolser, M.D., Section of Endocrinology and Metabolism, Children's Hospital, 678 William Avenue, Winnipeg, Manitoba R3E OWl Canada.

Twenty one patients with selective aldosterone deficiency due to type 2 corticosterone methyl-oxidase defect [hypoaldosteronism (HA)] and 7 with pseudohypoaldosteronism (PHA) were studied longitudinally for up to 18 yr. All individuals had spontaneous and progressive normalization of sodium and fluid balance with age. The severity of the clinical manifestations varied from acute salt-wasting crisis in infancy and unexplained short stature in childhood to an asymptomatic state in adults detectable only by biochemical studies. Infants with HA had extremely elevated plasma renin activity (PRA; 70–650 ng angiotensin I/ml: h), which gradually decreased with age, and PRA was normal in adults. Cortisol followed a similar pattern, but marked elevations of plasma deoxycorticosterone (DOC; 28-553 ng/dl) and 18-hydroxycorticosterone (18-OHB; 650-6500 ng/dl) relative to aldosterone (3–29 ng/dl) persisted throughout life in all untreated patients. The plasma 18-OHB/aldosterone ratio, normally 6.2 ± 3.5 (SD), ranged between 160–760. In contrast, patients with PHA had PRA (70–685 ng angiotensin 1/ml · h), DOC (56–1201 ng/dl), 18-OHB (650–6800 ng/dl), and aldosterone (150–2000 ng/dl) levels which all remained very elevated, but had normal 18-OHB/aldosterone ratios (6.9 ± 5.1). Comparative studies in 14 untreated patients with llβ-hydroxylase deficiency, who had moderate to severe manifestations of mineralocorticoid excess, revealed DOC levels (38–1384 ng/dl) that were remarkably similar to those of patients with HA and PHA. PRA, DOC, and 18-OHB correlated significantly with each other during all variations in sodium balance (P < 0.001). Sodium repletion partially suppressed these parameters in both disorders, but complete normalization was achieved only in HA when a mineralocorticoid was given. Although the degree of DOC and 18-OHB suppression was similar in all age groups, the changes in PRA were more marked in children than in adults since these were directly proportional to the initial elevations of PRA. Although angiotensin II and potassium increased plasma DOC and 18-OHB, dexamethasone failed to suppress them, indicating that these steroids originated predominantly from the zona glomerulosa.

The spontaneous normalization of sodium balance is not due to quantitative differences in hormone secretion with age since the basic steroid abnormalities remain unchanged from infancy to adulthood. Although aldosterone requirements normally decrease throughput life as renal transport mechanisms become more effective, the major compensatory mechanism operative in patients with PHA and HA is progressive improvement in renal tubular responsiveness to mineralocorticoids. On the other hand, in HA, infantile salt-wasting unresponsive to endogenous mineralocorticoids may also be attributed to the effect of a natriuretic factor, whose exact nature remains to be determined.

^* This work was supported in part by a grant from the Joint Research Fund of the Hebrew University and Hadassah. Presented in part at the Annual Meeting of the Israeli Endocrine Society, Tel-Aviv, Israel, January 1984 (Isr J Med Sci, in press).

Received January 31, 1984.

This article has been cited by other articles:

				K. Lovas, I. McFarlane, H.-H. Nguyen, S. Curran, J. Schwabe, D. Halsall, R. Bernhardt, A. M. Wallace, and V. K. K. Chatterjee A Novel CYP11B2 Gene Mutation in an Asian Family with Aldosterone Synthase Deficiency J. Clin. Endocrinol. Metab., March 1, 2009; 94(3): 914 - 919. [Abstract] [Full Text] [PDF]

				N. Makhanova, M. L.S. Sequeira-Lopez, R. A. Gomez, H.-S. Kim, and O. Smithies Disturbed Homeostasis in Sodium-Restricted Mice Heterozygous and Homozygous for Aldosterone Synthase Gene Disruption Hypertension, December 1, 2006; 48(6): 1151 - 1159. [Abstract] [Full Text] [PDF]

				N. Makhanova, G. Lee, N. Takahashi, M. L. Sequeira Lopez, R. A. Gomez, H.-S. Kim, and O. Smithies Kidney function in mice lacking aldosterone Am J Physiol Renal Physiol, January 1, 2006; 290(1): F61 - F69. [Abstract] [Full Text] [PDF]

				T. A. Williams, P. Mulatero, M. Bosio, S. Lewicka, M. Palermo, F. Veglio, and D. Armanini A Particular Phenotype in a Girl with Aldosterone Synthase Deficiency J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3168 - 3172. [Abstract] [Full Text] [PDF]

				W. L. Miller Steroid 17{alpha}-Hydroxylase Deficiency--Not Rare Everywhere J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 40 - 42. [Full Text] [PDF]

				A. Saxena, I. Hanukoglu, D. Saxena, R. J. Thompson, R. M. Gardiner, and A. Hanukoglu Novel Mutations Responsible for Autosomal Recessive Multisystem Pseudohypoaldosteronism and Sequence Variants in Epithelial Sodium Channel {alpha}-, {beta}-, and {gamma}-Subunit Genes J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3344 - 3350. [Abstract] [Full Text] [PDF]

				K. M. Kayes-Wandover, R. E. L. Schindler, H. C. Taylor, and P. C. White Type 1 Aldosterone Synthase Deficiency Presenting in a Middle-Aged Man J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1008 - 1012. [Abstract] [Full Text]

				T. Tajima, H. Kitagawa, S. Yokoya, K. Tachibana, M. Adachi, J. Nakae, S. Suwa, S. Katoh, and K. Fujieda A Novel Missense Mutation of Mineralocorticoid Receptor Gene in One Japanese Family with a Renal Form of Pseudohypoaldosteronism Type 1 J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4690 - 4694. [Abstract] [Full Text]

				E. Hummler and J.-D. Horisberger V. The epithelial sodium channel and its implication in human diseases Am J Physiol Gastrointest Liver Physiol, March 1, 1999; 276(3): G567 - G571. [Abstract] [Full Text] [PDF]

				S. Pradervand, P. M. Barker, Q. Wang, S. A. Ernst, F. Beermann, B. R. Grubb, M. Burnier, A. Schmidt, R. J. M. Bindels, J. T. Gatzy, et al. Salt restriction induces pseudohypoaldosteronism type 1 in mice expressing low levels of the beta -subunit of the amiloride-sensitive epithelial sodium channel PNAS, February 16, 1999; 96(4): 1732 - 1737. [Abstract] [Full Text] [PDF]

				A. T. Reutens, J. C. Achermann, M. Ito, M. Ito, W.-X. Gu, R. L. Habiby, P. A. Donohoue, S. Pang, P. C. Hindmarsh, and J. L. Jameson Clinical and Functional Effects of Mutations in the DAX-1 Gene in Patients with Adrenal Hypoplasia Congenita J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 504 - 511. [Abstract] [Full Text]

				M. Peter, L. Fawaz, S. L. S. Drop, H. K. A. Visser, and W. G. Sippell Hereditary Defect in Biosynthesis of Aldosterone: Aldosterone Synthase Deficiency 1964-1997 J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3525 - 3528. [Abstract] [Full Text] [PDF]

				E. Hummler, P. Barker, C. Talbot, Q. Wang, C. Verdumo, B. Grubb, J. Gatzy, M. Burnier, J.-D. Horisberger, F. Beermann, et al. A mouse model for the renal salt-wasting syndrome pseudohypoaldosteronism PNAS, October 14, 1997; 94(21): 11710 - 11715. [Abstract] [Full Text] [PDF]

				P. C. White Disorders of Aldosterone Biosynthesis and Action N. Engl. J. Med., July 28, 1994; 331(4): 250 - 258. [Full Text]

				D. B. Allen Defective Aldosterone Synthesis Associated With Hyperkalemic Periodic Paralysis Arch Neurol, March 1, 1993; 50(3): 325 - 328. [Abstract] [PDF]

				J. K. Smith and S. F. Kemp Pseudohypoaldosteronism: Successful Treatment with Home Electrolyte Monitoring Clinical Pediatrics, October 1, 1991; 30(10): 600 - 601. [PDF]